Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| B1801046 | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
People affected by rheumatoid arthritis are often suffering from fatigue and decreased QOL. In this study we are measuring the impact of SC biologics on these parameters.
Observational prospective study Purely descriptive
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RA Patients treated with SC anti-TNF |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SC anti-TNF | Other | SC anti-TNF |
|
| Measure | Description | Time Frame |
|---|---|---|
| Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Baseline | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | Baseline |
| Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 6 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | Month 6 |
| Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 12 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analog Scale (VAS) Fatigue Score | Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. | Baseline, Month 6, 12, 18, 24 |
| Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (DAS 28-ESR) |
| Measure | Description | Time Frame |
|---|---|---|
| Spearman Correlation Coefficient Between Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Components and Visual Analog Scale (VAS) Fatigue Score | Spearman correlation coefficient between AIMS2 component score and VAS fatigue score (AIMS2 component score versus [vs] VAS fatigue) was calculated. AIMS2 : 78-item questionnaire assessing 12 scales. Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain); total score range from 0 to 10, higher scores indicates worse situation and VAS score: Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. |
Inclusion Criteria:
Patients who:
Exclusion Criteria:
Use of biologics (or any experimental drug) in the last 3 months before initiation of SC anti-TNF-α therapy.
Participation in other clinical or observational trials
Not provided
Not provided
Not provided
patients seen in a rheumatology practice
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UZ Gasthuisberg | Leuven | 3000 | Belgium |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Anti-Tumour Necrosis Factor Alpha (Anti-TNF-alpha) | Participants with rheumatoid arthritis (RA), who received subcutaneous anti-TNF-alpha therapy along with methotrexate as per treating physician's discretion based on summary of product characteristics, were followed up for 2 years. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Intention to treat (ITT) population included all participants for whom the primary endpoint or one of the secondary endpoints could be determined at baseline. Here "N" (Overall Number of Baseline Participants) includes participants with non-missing baseline data.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Anti-Tumour Necrosis Factor Alpha (Anti-TNF-alpha) | Participants with rheumatoid arthritis (RA), who received subcutaneous anti-TNF-alpha therapy along with methotrexate as per treating physician's discretion based on summary of product characteristics, were followed up for 2 years. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Baseline | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Mean | Standard Deviation | units on a scale | Baseline |
Not provided
The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Anti-Tumour Necrosis Factor Alpha (Anti-TNF-alpha) | Participants with rheumatoid arthritis (RA), who received subcutaneous anti-TNF-alpha therapy along with methotrexate as per treating physician's discretion based on summary of product characteristics, were followed up for 2 years. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Spondylodiscitis | General disorders | MedDRA 14.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Asthma | General disorders | MedDRA 14.0 | Non-systematic Assessment |
Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Month 12 |
| Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 18 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | Month 18 |
| Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 24 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | Month 24 |
DAS28-ESR was calculated from the number of swollen joints (SJC) and tender joints (TJC ) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeter per hour [mm/hour]) and participant's assessment of disease activity visual analog scale (scores ranging 0 [very well] to 100 mm [extremely bad]). Total score range: 0-10, higher score=more disease activity (DA). DAS28-ESR less than equal to (<=) 3.2 = low disease activity, DAS28 greater than (>) 3.2 to 5.1 = moderate to high DA |
| Baseline, Month 6, 12, 18, 24 |
| Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS 28-CRP) | DAS28-CRP was calculated from the number of swollen joints ( SJC) and tender joints (TJC) count using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0-10, higher score= more disease activity. DAS28 (CRP) : <3.2= low disease activity, >3.2 to 5.1 = moderate to high disease activity and less than (<)2.6 = remission. | Baseline, Month 6, 12, 18, 24 |
| Health Assessment Questionnaire (HAQ) Total Score | HAQ: 20-item participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of item scores. HAQ total score was 0 to 60 (as used in Belgium), where greater score indicated greater difficulty. | Baseline, Month 6, 12, 18, 24 |
| Baseline, Month 6, 12, 18, 24 |
| Pearson Correlation Coefficient Between Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Components and Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation (DAS 28-ESR) | Pearson correlation coefficient between AIMS2 component score and DAS28-ESR score (AIMS2 component score vs DAS28-ESR) was calculated. AIMS2: 78-item questionnaire assessing 12 scales. Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain); total score range from 0 to 10, higher scores indicates worse situation and DAS28-ESR calculated from the number of SJC and TJC using the 28 joints count, ESR (mm/hour) and participant's assessment of disease activity VAS (scores ranging 0 [very well] to 100 mm [extremely bad]). Total score range: 0-10, higher score= more disease activity. DAS28-ESR <= 3.2 = low DA, DAS28 > 3.2 to 5.1 = moderate to high DA. | Baseline, Month 6,1 2, 18, 24 |
| Pearson Correlation Coefficient Between Arthritis Impact Measurement Scale- Version 2 (AIMS2) Main Components and Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS 28-CRP) | Pearson correlation coefficient between AIMS2 component score and DAS28-CRP score (AIMS2 component score vs DAS28-CRP) was calculated. AIMS2: 78-item questionnaire assessing 12 scales. Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain); total score range from 0 to 10, higher scores indicates worse situation DAS28-CRP was calculated from the number of SJC and TJC count using 28 joint count and CRP (mg/L). Total score range: 0-10, higher score= more disease activity. DAS28 (CRP): <3.2= low DA, >3.2 to 5.1 = moderate to high DA and <2.6 = remission. | Baseline, Month 6, 12, 18, 24 |
| Spearman Correlation Coefficient Between Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation (DAS 28-ESR) and Visual Analog Scale (VAS) Fatigue Score | Spearman correlation coefficient between DAS28-ESR and VAS fatigue (DAS28-ESR vs VAS score) was calculated. DAS28-ESR calculated from the number of SJC and TJC using the 28 joints count, ESR (mm/hour) and participant's assessment of disease activity VAS (scores ranging 0 [very well] to 100 mm [extremely bad]). Total score range: 0-10, higher score= more disease activity. DAS28-ESR <= 3.2 = low DA, DAS28 > 3.2 to 5.1 = moderate to high DA and VAS fatigue = Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. | Baseline, Month 6, 12, 18, 24 |
| Spearman Correlation Coefficient Between Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS 28-CRP) and Visual Analog Scale (VAS) Fatigue Score | Spearman correlation coefficient between DAS28-CRP and VAS score (DAS28-CRP vs VAS score) was calculated. DAS28-CRP was calculated from the number of SJC and TJC count using 28 joint count and CRP (mg/L). Total score range: 0-10, higher score= more disease activity. DAS28 (CRP): <3.2= low DA, >3.2 to 5.1 = moderate to high DA and <2.6 = remission and VAS= Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. | Baseline, Month 6, 12, 18, 24 |
| Withdrawal by Subject |
|
| Physician Decision |
|
| Protocol Violation |
|
| Participant non-eligible |
|
| Lost to Follow-up |
|
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
|
|
|
| Primary | Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 6 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Mean | Standard Deviation | units on a scale | Month 6 |
|
|
|
| Primary | Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 12 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "N" (number of participants analyzed) = participants who were evaluable for this measure. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Mean | Standard Deviation | units on a scale | Month 12 |
|
|
|
| Primary | Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 18 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Mean | Standard Deviation | units on a scale | Month 18 |
|
|
|
| Primary | Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Component Score at Month 24 | AIMS2 is a disease-specific measure of physical, social, and emotional well-being. It is a 78-item questionnaire assessing 12 scales: moving capacities, walking and dexterity, hand and fingers movements, arm movements, self-care, household activities, social activities, support of family and friends, joint pain, work, nervous tension and psychological condition (anxiety and depression). Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain) with total score range from 0 to 10 for all component scores, where higher scores indicated worse situation. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Mean | Standard Deviation | units on a scale | Month 24 |
|
|
|
| Secondary | Visual Analog Scale (VAS) Fatigue Score | Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Month 6, 12, 18, 24 |
|
|
|
| Secondary | Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (DAS 28-ESR) | DAS28-ESR was calculated from the number of swollen joints (SJC) and tender joints (TJC ) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeter per hour [mm/hour]) and participant's assessment of disease activity visual analog scale (scores ranging 0 [very well] to 100 mm [extremely bad]). Total score range: 0-10, higher score=more disease activity (DA). DAS28-ESR less than equal to (<=) 3.2 = low disease activity, DAS28 greater than (>) 3.2 to 5.1 = moderate to high DA | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Month 6, 12, 18, 24 |
|
|
|
| Secondary | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS 28-CRP) | DAS28-CRP was calculated from the number of swollen joints ( SJC) and tender joints (TJC) count using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0-10, higher score= more disease activity. DAS28 (CRP) : <3.2= low disease activity, >3.2 to 5.1 = moderate to high disease activity and less than (<)2.6 = remission. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Month 6, 12, 18, 24 |
|
|
|
| Secondary | Health Assessment Questionnaire (HAQ) Total Score | HAQ: 20-item participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Each item scored on 4-point scale, 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of item scores. HAQ total score was 0 to 60 (as used in Belgium), where greater score indicated greater difficulty. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. | Posted | Mean | Standard Deviation | units on a scale | Baseline, Month 6, 12, 18, 24 |
|
|
|
| Other Pre-specified | Spearman Correlation Coefficient Between Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Components and Visual Analog Scale (VAS) Fatigue Score | Spearman correlation coefficient between AIMS2 component score and VAS fatigue score (AIMS2 component score versus [vs] VAS fatigue) was calculated. AIMS2 : 78-item questionnaire assessing 12 scales. Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain); total score range from 0 to 10, higher scores indicates worse situation and VAS score: Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Number | correlation coefficient | Baseline, Month 6, 12, 18, 24 |
|
|
|
| Other Pre-specified | Pearson Correlation Coefficient Between Arthritis Impact Measurement Scale - Version 2 (AIMS2) Main Components and Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation (DAS 28-ESR) | Pearson correlation coefficient between AIMS2 component score and DAS28-ESR score (AIMS2 component score vs DAS28-ESR) was calculated. AIMS2: 78-item questionnaire assessing 12 scales. Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain); total score range from 0 to 10, higher scores indicates worse situation and DAS28-ESR calculated from the number of SJC and TJC using the 28 joints count, ESR (mm/hour) and participant's assessment of disease activity VAS (scores ranging 0 [very well] to 100 mm [extremely bad]). Total score range: 0-10, higher score= more disease activity. DAS28-ESR <= 3.2 = low DA, DAS28 > 3.2 to 5.1 = moderate to high DA. | ITT population, Here "n" = participants evaluable for this measure for specified component score and "N" (number of participants analyzed) = participants who were evaluable for this measure. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Number | correlation coefficient | Baseline, Month 6,1 2, 18, 24 |
|
|
|
| Other Pre-specified | Pearson Correlation Coefficient Between Arthritis Impact Measurement Scale- Version 2 (AIMS2) Main Components and Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS 28-CRP) | Pearson correlation coefficient between AIMS2 component score and DAS28-CRP score (AIMS2 component score vs DAS28-CRP) was calculated. AIMS2: 78-item questionnaire assessing 12 scales. Each item was scored as 0 (or 1, best situation) to 4 (worst situation). Sub-total score of each of the 12 scales normalized to a maximum of 10. Total score were calculated for AIMS2 Affect ([Level of tension + Mood]/2), AIMS2 Physical ([Mobility level + Walking and bending + Hand and finger function + Arm function + Self Care + Household tasks]/6), and AIMS2 Symptom (Arthritis pain); total score range from 0 to 10, higher scores indicates worse situation DAS28-CRP was calculated from the number of SJC and TJC count using 28 joint count and CRP (mg/L). Total score range: 0-10, higher score= more disease activity. DAS28 (CRP): <3.2= low DA, >3.2 to 5.1 = moderate to high DA and <2.6 = remission. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. The results for social interaction and role components of AIMS2 were not analyzed due to change in planned analysis. | Posted | Number | correlation coefficient | Baseline, Month 6, 12, 18, 24 |
|
|
|
| Other Pre-specified | Spearman Correlation Coefficient Between Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation (DAS 28-ESR) and Visual Analog Scale (VAS) Fatigue Score | Spearman correlation coefficient between DAS28-ESR and VAS fatigue (DAS28-ESR vs VAS score) was calculated. DAS28-ESR calculated from the number of SJC and TJC using the 28 joints count, ESR (mm/hour) and participant's assessment of disease activity VAS (scores ranging 0 [very well] to 100 mm [extremely bad]). Total score range: 0-10, higher score= more disease activity. DAS28-ESR <= 3.2 = low DA, DAS28 > 3.2 to 5.1 = moderate to high DA and VAS fatigue = Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. | Posted | Number | correlation coefficient | Baseline, Month 6, 12, 18, 24 |
|
|
|
| Other Pre-specified | Spearman Correlation Coefficient Between Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS 28-CRP) and Visual Analog Scale (VAS) Fatigue Score | Spearman correlation coefficient between DAS28-CRP and VAS score (DAS28-CRP vs VAS score) was calculated. DAS28-CRP was calculated from the number of SJC and TJC count using 28 joint count and CRP (mg/L). Total score range: 0-10, higher score= more disease activity. DAS28 (CRP): <3.2= low DA, >3.2 to 5.1 = moderate to high DA and <2.6 = remission and VAS= Participants recorded their fatigue score on a range of 0 to 10, where higher score indicated higher intensity of fatigue. | ITT population included participants for whom the primary endpoint or 1 of the secondary endpoints could be determined at baseline. Here "n" = participants who were evaluable for this measure for specified component score. | Posted | Number | correlation coefficient | Baseline, Month 6, 12, 18, 24 |
|
|
|
| 1 |
| 62 |
| 4 |
| 62 |
| Tachycardia | General disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Headache | General disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Nausea | General disorders | MedDRA 14.0 | Non-systematic Assessment |
|
| Purulent rhinorrhea | General disorders | MedDRA 14.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Month 18 (n=31) |
|
| Month 24 (n=30) |
|
| Title | Measurements |
|---|---|
|
| Month 18 (n=24) |
|
| Month 24 (n=23) |
|
| Title | Measurements |
|---|---|
|
| Month 18 (n=21) |
|
| Month 24 (n=19) |
|
| Title | Measurements |
|---|---|
|
| Month 18 (n=32) |
|
| Month 24 (n=31) |
|
| Title | Measurements |
|---|---|
|
| Month 6: AIMS2 Physical vs VAS fatigue (n=45) |
|
| Month 6: AIMS2 Affect at vs VAS fatigue (n=47) |
|
| Month 6: AIMS2 Symptom vs VAS fatigue (n=47) |
|
| Month 12: AIMS2 Physical vs VAS fatigue (n=41) |
|
| Month 12: AIMS2 Affect vs VAS fatigue (n=41) |
|
| Month 12: AIMS2 Symptom vs VAS fatigue (n=41) |
|
| Month 18: AIMS2 Physical vs VAS fatigue (n=30) |
|
| Month 18: AIMS2 Affect vs VAS fatigue (n=31) |
|
| Month 18: AIMS2 Symptom vs VAS fatigue (n=31) |
|
| Month 24: AIMS2 Physical vs VAS fatigue (n=30) |
|
| Month 24: AIMS2 Affect vs VAS fatigue (n=30) |
|
| Month 24: AIMS2 Symptom vs VAS fatigue (n=29) |
|
| Title | Measurements |
|---|---|
|
| Month 6: AIMS2 Physical vs DAS28-ESR (n=38) |
|
| Month 6: AIMS2 Affect vs DAS28-ESR (n=40) |
|
| Month 6: AIMS2 Symptom vs DAS28-ESR (n=40) |
|
| Month 12: AIMS2 Physical vs DAS28-ESR (n=33) |
|
| Month 12: AIMS2 Affect vs DAS28-ESR (n=33) |
|
| Month 12: AIMS2 Symptom vs DAS28-ESR (n=33) |
|
| Month 18: AIMS2 Physical vs DAS28-ESR (n=20) |
|
| Month 18: AIMS2 Affect vs DAS28-ESR (n=21) |
|
| Month 18: AIMS2 Symptom vs DAS28-ESR (n=21) |
|
| Month 24: AIMS2 Physical vs DAS28-ESR (n=21) |
|
| Month 24: AIMS2 Affect vs DAS28-ESR (n=21) |
|
| Month 24: AIMS2 Symptom vs DAS28-ESR (n=20) |
|
| Title | Measurements |
|---|---|
|
| Month 6: AIMS2 Physical vs DAS 28-CRP (n=19) |
|
| Month 6: AIMS2 Affect vs DAS 28-CRP (n=20) |
|
| Month 6: AIMS2 Symptom vs DAS 28-CRP (n=20) |
|
| Month 12: AIMS2 Physical vs DAS 28-CRP (n=19) |
|
| Month 12: AIMS2 Affect vs DAS 28-CRP (n=19) |
|
| Month 12: AIMS2 Symptom vs DAS 28-CRP (n=19) |
|
| Month 18: AIMS2 Physical vs DAS 28-CRP (n=16) |
|
| Month 18: AIMS2 Affect vs DAS 28-CRP (n=16) |
|
| Month 18: AIMS2 Symptom vs DAS 28-CRP (n=16) |
|
| Month 24: AIMS2 Physical vs DAS 28-CRP (n=18) |
|
| Month 24: AIMS2 Affect vs DAS 28-CRP (n=18) |
|
| Month 24: AIMS2 Symptom vs DAS 28-CRP (n=18) |
|
| Title | Measurements |
|---|---|
|
| Month 18: DAS28-ESR vs VAS fatigue (n=21) |
|
| Month 24: DAS28-ESR vs VAS fatigue (n=21) |
|
| Title | Measurements |
|---|---|
|
| Month 18: DAS28-CRP vs VAS fatigue (n=16) |
|
| Month 24: DAS28-CRP vs VAS fatigue (n=17) |
|